HLA-DR Association in Papillary Thyroid Carcinoma

Amoli, Mahsa M.; Yazdani, Nasrin; Amiri, Parvin; Sayahzadeh, Forogh; Haghpanah, Vahid; Tavangar, Seyed Mohammad; Amirzargar, Ali Akbar; Ghaffari, Hamidollah; Nikbin, Behrooz; Larijani, Bagher; Mostaan, Leila Vazifeh; Bazzaz, Javad Tavakkoly

doi:10.1155/2010/130276

Cited by 16 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The inclusion criteria were as follows: epidemiological study, reporting expression of at least one HLA‐DR subgroup, presence of a control group of subjects without thyroid cancer, either directly reporting or permitting a calculation of prevalence ratios (PRs). The 13 selected studies are listed in Table 1(8–19). For each study we estimated the PR for a given HLA as PR = prevalence of thyroid cancer in subjects with a given HLA‐DR antigen/prevalence of thyroid cancer in subjects lacking that HLA‐DR antigen.…”

Section: Characteristics Of the Studies Included In Meta‐analysismentioning

confidence: 99%

Weak or absent evidence for the association of HLA‐DR antigens with risk of thyroid carcinoma: a meta‐analysis of observational studies

Kamdi¹,

Kandavalli²,

Emusu³

et al. 2011

Tissue Antigens

View full text Add to dashboard Cite

Inconsistent reports of associations between human leukocyte antigen (HLA)-DR and thyroid cancers exist. We conducted a comprehensive search of the PubMed, Scopus and Web of Science databases. Using random-effects modeling, subgroup analyses, meta-regression and prediction interval (PI) estimation, we combined the existing evidence from 13 studies (977 cases of thyroid cancer and 3735 controls). Only HLA-DR1 and HLA-DR11 were significantly associated; however, the evidence for HLA-DR11 came from only three studies while that for HLA-DR1 had large between-study heterogeneity. All the PIs estimated in the study straddled unity. Therefore, current evidence for the studied association is incomplete as well as uncertain. Attempts to include HLA-DR typing as a prognostic or therapeutic marker may be premature at this time.

show abstract

Section: Characteristics Of the Studies Included In Meta‐analysismentioning

confidence: 99%

Weak or absent evidence for the association of HLA‐DR antigens with risk of thyroid carcinoma: a meta‐analysis of observational studies

Kamdi¹,

Kandavalli²,

Emusu³

et al. 2011

Tissue Antigens

View full text Add to dashboard Cite

show abstract

“…28 Thyroid tumors represent the most prevalent and incident type of endocrine neoplasia, accounting for approximately 1% of all new cases diagnosed each year. 29,30 Data show how hereditary conditions, 31 along with gender and age, 32 low-iodine diet, 33 and radiation exposure, 34 play a significant role in the incidence of thyroid tumors. Thyroid tumors can be classified in differentiated (up to approximately 90% of all thyroid tumors), including PTC and FTC, and undifferentiated, such as ATC.…”

Section: Introductionmentioning

confidence: 99%

<p>miR-19a Is Involved In Progression And Malignancy Of Anaplastic Thyroid Cancer Cells</p>

Calabrese¹,

Dolcimascolo²,

Caruso³

et al. 2019

OTT

View full text Add to dashboard Cite

Background: MicroRNAs (miRNAs) are endogenous, single-stranded, non-coding RNAs acting as negative regulators of gene expression involved in a number of physiological processes. MiRNAs' expression is commonly dysregulated in many types of human tumor diseases and cancers, including thyroid cancers, and is often involved in tumor initiation and progression. miR-19a, a member of miR-17-92 cluster, has been demonstrated to promote cell growth in anaplastic thyroid cancer (ATC), the most advanced and aggressive thyroid cancer. Purpose: In this work, we investigate the potential contribution of miR-19a in thyroid cancer cells poor prognosis and de-differentiation. Methods: We directly modulated the expression of miR-19a in papillary (PTC) and anaplastic thyroid carcinoma cell lines through transfection of specific miR-19a mimic or inhibitor. Further, we performed gene expression analysis of specific genes to evaluate miR-19a association with cell cycle, differentiation, and poor prognosis. Results: Our data indicate that miR-19a overexpression in PTC cells significantly promotes cell growth, decreases the expression of differentiation genes and activates poor prognosis genes. Its inhibition in ATC cells reduces cell proliferation and the expression of genes related to poor prognosis but does not affect differentiation. Conclusion: Our findings reveal the existence of functional associations between miR-19a expression and thyroid cancer progression and malignancy suggesting miR-19a as a novel candidate therapeutic target for ATC.

show abstract

“…The classic treatment for thyroid cancer is thyroidectomy and adjuvant radioiodine ablation that most patients can be cured, but still surgically inoperative recurrence, refractoriness to radioiodine in DTC, poorly differentiated thyroid carcinoma and ATC are unsolved. In the same way to other solid cancers, thyroid cancer is commenced by genetic alterations and epigenetic changes in driver oncogenes or tumor suppressor genes (11)(12)(13)(14). Recent advancement of molecular technologies has brought a new insight to the thyroid tumors diagnosis and prognosis.…”

Section: Introductionmentioning

confidence: 99%

A Review of Driver Genetic Alterations in Thyroid Cancers

Khatami

Tavangar

2018

Iran J Pathol

View full text Add to dashboard Cite

Thyroid Cancer; Proto Oncogene Protein B raf; MAP kinase signaling system; Proto-Oncogene Proteins p21(ras) Thyroid cancer is a frequent endocrine related malignancy with continuous increasing incidence. There has been moving development in understanding its molecular pathogenesis recently mainly through the explanation of the original role of several key signaling pathways and related molecular distributors. Central to these mechanisms are the genetic and epigenetic alterations in these pathways, such as mutation and DNA rearrangements. That does not mean, however, that all the somatic abnormalities here in a cancer genome have been involved in development of the cancer and just driver mutations are concerned in tumor initiation. By way of illustrations, MAPK pathway which is motivated by BRAF V600E and RAS and RET / PTC rearrangements are suggesting driver genetic alterations in follicular derived thyroid cancers which are considered in this review.

show abstract

HLA-DR Association in Papillary Thyroid Carcinoma

Cited by 16 publications

References 19 publications

Weak or absent evidence for the association of HLA‐DR antigens with risk of thyroid carcinoma: a meta‐analysis of observational studies

Weak or absent evidence for the association of HLA‐DR antigens with risk of thyroid carcinoma: a meta‐analysis of observational studies

<p>miR-19a Is Involved In Progression And Malignancy Of Anaplastic Thyroid Cancer Cells</p>

A Review of Driver Genetic Alterations in Thyroid Cancers

Contact Info

Product

Resources

About